Literature DB >> 21135877

Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.

Vahakn B Shahinian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21135877     DOI： 10.1038/nrurol.2010.210

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Ronald A Morton; K Gary Barnette; Paul R Sieber; S Bruce Malkowicz; Domingo Rodriguez; Michael L Hancock; Mitchell S Steiner
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Authors:  Susan L Greenspan; Joel B Nelson; Donald L Trump; Neil M Resnick
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

3.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Matthew R Smith
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

Review 4.  Intermittent androgen suppression for prostate cancer.

Authors:  Nicholas C Buchan; S Larry Goldenberg
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

5.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

6.  Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

Authors:  Deborah Grady; Bruce Ettinger; Elena Moscarelli; Leo Plouffe; Somnath Sarkar; Angelina Ciaccia; Steven Cummings
Journal:  Obstet Gynecol       Date:  2004-10       Impact factor: 7.661

7.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

8.  Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.

Authors:  Scott M Gilbert; Yong-Fang Kuo; Vahakn B Shahinian
Journal:  Urol Oncol       Date:  2009-11-19       Impact factor: 3.498

9.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245
  9 in total
  3 in total

1.  Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice.

Authors:  Huei-Ting Tsai; David Penson; George Luta; John H Lynch; Yingjun Zhou; Arnold L Potosky
Journal:  Urol Pract       Date:  2015-07

2.  Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo
Journal:  J Gen Intern Med       Date:  2013-05-14       Impact factor: 5.128

3.  Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.

Authors:  Gerhard Hamilton; Ulrike Olszewski-Hamilton; Gerhard Theyer
Journal:  Cancers (Basel)       Date:  2011-09-15       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.